Effects of Oxysterols on Immune Cells and Related Diseases

Carregando...
Imagem de Miniatura
Citações na Scopus
18
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Citação
CELLS, v.11, n.8, article ID 1251, 26p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Oxysterols are the products of cholesterol oxidation. They have a wide range of effects on several cells, organs, and systems in the body. Oxysterols also have an influence on the physiology of the immune system, from immune cell maturation and migration to innate and humoral immune responses. In this regard, oxysterols have been involved in several diseases that have an immune component, from autoimmune and neurodegenerative diseases to inflammatory diseases, atherosclerosis, and cancer. Here, we review data on the participation of oxysterols, mainly 25-hydroxycholesterol and 7 alpha,25-dihydroxycholesterol, in the immune system and related diseases. The effects of these oxysterols and main oxysterol receptors, LXR and EBI2, in cells of the immune system (B cells, T cells, macrophages, dendritic cells, oligodendrocytes, and astrocytes), and in immune-related diseases, such as neurodegenerative diseases, intestinal diseases, cancer, respiratory diseases, and atherosclerosis, are discussed.
Palavras-chave
oxysterols, 25-hydroxycholesterol, 7 alpha,25-dihydroxycholesterol, immune cells, immune diseases, EBI2, LXR
Referências
  1. Abdel-Khalik J, 2017, J LIPID RES, V58, P267, DOI 10.1194/jlr.P071639
  2. Abildayeva K, 2006, J BIOL CHEM, V281, P12799, DOI 10.1074/jbc.M601019200
  3. Amisten S, 2008, THROMB RES, V122, P47, DOI 10.1016/j.thromres.2007.08.014
  4. Arfelt KN, 2017, BLOOD, V129, P866, DOI 10.1182/blood-2016-02-697185
  5. Baek AE, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00910-z
  6. Bah SY, 2017, J STEROID BIOCHEM, V169, P152, DOI 10.1016/j.jsbmb.2016.04.015
  7. Barington L, 2018, J LEUKOCYTE BIOL, V104, P313, DOI 10.1002/JLB.2VMR1217-510R
  8. Bartlett S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.601534
  9. Bauman DR, 2009, P NATL ACAD SCI USA, V106, P16764, DOI 10.1073/pnas.0909142106
  10. Benned-Jensen T, 2013, FEBS OPEN BIO, V3, P156, DOI 10.1016/j.fob.2013.02.003
  11. Benned-Jensen T, 2011, J BIOL CHEM, V286, P29292, DOI 10.1074/jbc.M110.196345
  12. Forwell AL, 2016, J NEUROIMMUNOL, V291, P70, DOI 10.1016/j.jneuroim.2015.12.014
  13. Galea E, 2012, BBA-MOL BASIS DIS, V1822, P1475, DOI 10.1016/j.bbadis.2012.02.005
  14. Gatto D, 2013, TRENDS IMMUNOL, V34, P336, DOI 10.1016/j.it.2013.01.007
  15. Gatto D, 2009, IMMUNITY, V31, P259, DOI 10.1016/j.immuni.2009.06.016
  16. Geyeregger R, 2007, BLOOD, V109, P4288, DOI 10.1182/blood-2006-08-043422
  17. Ghisletti S, 2007, MOL CELL, V25, P57, DOI 10.1016/j.molcel.2006.11.022
  18. Glass CK, 2000, GENE DEV, V14, P121
  19. Goenka A., 2017, UKPIN C BRIGHT UK
  20. Griffiths WJ, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.723224
  21. Griffiths WJ, 2018, BIOCHEM BIOPH RES CO, V504, P617, DOI 10.1016/j.bbrc.2018.02.019
  22. Pereira JP, 2009, NATURE, V460, P1122, DOI 10.1038/nature08226
  23. Griffiths WJ, 2016, BIOCHEM SOC T, V44, P652, DOI 10.1042/BST20150255
  24. Hannedouche S, 2011, NATURE, V475, P524, DOI 10.1038/nature10280
  25. Hashimoto Y, 2016, AM J PHYSIOL-LUNG C, V310, pL1028, DOI 10.1152/ajplung.00351.2015
  26. Heinig M, 2010, NATURE, V467, P460, DOI 10.1038/nature09386
  27. Honda A, 2011, J LIPID RES, V52, P1509, DOI 10.1194/jlr.M014084
  28. Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593
  29. Hubler MJ, 2016, J NUTR BIOCHEM, V34, P1, DOI 10.1016/j.jnutbio.2015.11.002
  30. Iborra RT, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-172
  31. Ishikawa T, 2013, J CLIN INVEST, V123, P3488, DOI 10.1172/JCI66533
  32. Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0
  33. PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6
  34. Jarvis S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215379
  35. Jessup W, 2002, VASC PHARMACOL, V38, P239, DOI 10.1016/S1537-1891(02)00174-X
  36. Jia J, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708349
  37. Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032
  38. Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582
  39. Kanner J, 2007, MOL NUTR FOOD RES, V51, P1094, DOI 10.1002/mnfr.200600303
  40. Ki S, 2017, EUR J IMMUNOL, V47, P1906, DOI 10.1002/eji.201747020
  41. Kikuchi T, 2012, CHEST, V142, P329, DOI 10.1378/chest.11-2091
  42. Kim Dayea, 2022, Advances in Biological Regulation, V83, P100837, DOI 10.1016/j.jbior.2021.100837
  43. Kim SM, 2017, ONCOTARGET, V8, P11855, DOI 10.18632/oncotarget.14416
  44. Perucha E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08332-9
  45. Kimura T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13130
  46. Kloudova-Spalenkova A, 2021, BRIT J PHARMACOL, V178, P3235, DOI 10.1111/bph.15273
  47. Korf H, 2009, J CLIN INVEST, V119, P1626, DOI 10.1172/JCI35288
  48. Lanterna C, 2016, CANCER IMMUNOL IMMUN, V65, P1303, DOI 10.1007/s00262-016-1884-8
  49. Lathe R, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-36
  50. Lemaire-Ewing S, 2005, CELL BIOL TOXICOL, V21, P97, DOI 10.1007/s10565-005-0141-2
  51. Levy D, 2019, BIOCHEM BIOPHYS REP, V19, DOI 10.1016/j.bbrep.2018.12.008
  52. Levy D, 2018, BIOCHEM BIOPH RES CO, V505, P1043, DOI 10.1016/j.bbrc.2018.10.008
  53. Levy D, 2014, BIOCHEM BIOPH RES CO, V446, P720, DOI 10.1016/j.bbrc.2014.01.132
  54. Li Z, 2017, CIRCULATION, V136, P1315, DOI 10.1161/CIRCULATIONAHA.117.027462
  55. Petrov AM, 2019, NEUROTHERAPEUTICS, V16, P635, DOI 10.1007/s13311-019-00731-6
  56. Linsenbardt AJ, 2014, NEUROPHARMACOLOGY, V85, P232, DOI 10.1016/j.neuropharm.2014.05.027
  57. Liu CL, 2011, NATURE, V475, P519, DOI 10.1038/nature10226
  58. Marengo B, 2016, BIOFACTORS, V42, P80, DOI 10.1002/biof.1243
  59. Mascia C, 2010, FREE RADICAL BIO MED, V49, P2049, DOI 10.1016/j.freeradbiomed.2010.09.033
  60. Maxwell KF, 2019, J LIPID RES, V60, P1190, DOI 10.1194/jlr.M089664
  61. McDonald JG, 2007, METHOD ENZYMOL, V432, P145, DOI 10.1016/S0076-6879(07)32006-5
  62. McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
  63. Moutinho M, 2016, BBA-MOL CELL BIOL L, V1861, P1911, DOI 10.1016/j.bbalip.2016.09.011
  64. Mouzat K, 2018, MOL NEUROBIOL, V55, P1959, DOI 10.1007/s12035-017-0453-2
  65. Mukhutdinova KA, 2019, NEUROPHARMACOLOGY, V150, P70, DOI 10.1016/j.neuropharm.2019.03.018
  66. Plat J, 2005, J LIPID RES, V46, P2468, DOI 10.1194/jlr.M500272-JLR200
  67. Mukhutdinova KA, 2018, MOL CELL NEUROSCI, V88, P308, DOI 10.1016/j.mcn.2018.03.006
  68. Mutemberezi V, 2016, PROG LIPID RES, V64, P152, DOI 10.1016/j.plipres.2016.09.002
  69. Myers BR, 2013, DEV CELL, V26, P346, DOI 10.1016/j.devcel.2013.07.015
  70. Nachtergaele S, 2012, NAT CHEM BIOL, V8, P211, DOI 10.1038/nchembio.765
  71. Nevius E, 2015, J EXP MED, V212, P1931, DOI 10.1084/jem.20150088
  72. Ngo MD, 2022, J INFECT DIS, DOI 10.1093/infdis/jiac102
  73. Odnoshivkina UG, 2019, LIFE SCI, V220, P117, DOI 10.1016/j.lfs.2019.01.054
  74. Olkkonen VM, 2012, CURR OPIN LIPIDOL, V23, P462, DOI 10.1097/MOL.0b013e328356dba0
  75. Ouyang W, 2018, J CELL MOL MED, V22, P5494, DOI 10.1111/jcmm.13820
  76. Parekh D, 2011, CLIN MED, V11, P615, DOI 10.7861/clinmedicine.11-6-615
  77. Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007
  78. Park K, 2010, J LEUKOCYTE BIOL, V88, P1081, DOI 10.1189/jlb.0610318
  79. Prunet C, 2006, CYTOM PART A, V69A, P359, DOI 10.1002/cyto.a.20272
  80. Raccosta L, 2016, CANCER IMMUNOL IMMUN, V65, P111, DOI 10.1007/s00262-015-1779-0
  81. Raccosta L, 2013, J EXP MED, V210, P1711, DOI 10.1084/jem.20130440
  82. Ragot K, 2013, BIOCHEM PHARMACOL, V86, P67, DOI 10.1016/j.bcp.2013.02.028
  83. Bensinger SJ, 2008, CELL, V134, P97, DOI 10.1016/j.cell.2008.04.052
  84. Ragot K, 2011, CHEM PHYS LIPIDS, V164, P469, DOI 10.1016/j.chemphyslip.2011.04.014
  85. Raherison C, 2009, EUR RESPIR REV, V18, P213, DOI 10.1183/09059180.00003609
  86. Raselli T, 2019, J CROHNS COLITIS, V13, P1186, DOI 10.1093/ecco-jcc/jjz039
  87. Reboldi A, 2014, SCIENCE, V345, P679, DOI 10.1126/science.1254790
  88. Reinmuth L, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10082078
  89. Rosa-Fernandes L, 2017, CHEM PHYS LIPIDS, V207, P231, DOI 10.1016/j.chemphyslip.2017.06.008
  90. Rosenkilde MM, 2006, J BIOL CHEM, V281, P13199, DOI 10.1074/jbc.M602245200
  91. Rossin D, 2017, FREE RADICAL BIO MED, V111, P186, DOI 10.1016/j.freeradbiomed.2017.01.017
  92. Ruiz JLM, 2013, BIOCHEM PHARMACOL, V86, P80, DOI 10.1016/j.bcp.2013.02.033
  93. Russell DW, 2009, ANNU REV BIOCHEM, V78, P1017, DOI 10.1146/annurev.biochem.78.072407.103859
  94. Biasi F, 2008, CARCINOGENESIS, V29, P890, DOI 10.1093/carcin/bgn106
  95. Rutkowska A, 2016, CURR DRUG TARGETS, V17, P1851, DOI 10.2174/1389450117666160217123042
  96. Rutkowska A, 2015, GLIA, V63, P341, DOI 10.1002/glia.22757
  97. Rydberg EK, 2003, ATHEROSCLEROSIS, V170, P245, DOI 10.1016/S0021-9150(03)00302-2
  98. Sensi C, 2014, CELL SIGNAL, V26, P2614, DOI 10.1016/j.cellsig.2014.08.003
  99. Shahoei SH, 2019, J STEROID BIOCHEM, V191, DOI 10.1016/j.jsbmb.2019.04.013
  100. Shen ZJ, 2017, AM J RESP CRIT CARE, V195, P1576, DOI [10.1164/rccm.201608-1580OC, 10.1164/rccm.201608-1580oc]
  101. Shibata N, 2010, CIRC J, V74, P2045, DOI 10.1253/circj.CJ-10-0860
  102. Silva SF, 2017, J STEROID BIOCHEM, V169, P164, DOI 10.1016/j.jsbmb.2016.04.017
  103. Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8
  104. Sodero AO, 2021, J NEUROCHEM, V157, P899, DOI 10.1111/jnc.15228
  105. Biasi F, 2009, FREE RADICAL BIO MED, V47, P1731, DOI 10.1016/j.freeradbiomed.2009.09.020
  106. Soroosh P, 2014, P NATL ACAD SCI USA, V111, P12163, DOI 10.1073/pnas.1322807111
  107. Spann NJ, 2013, NAT IMMUNOL, V14, P893, DOI 10.1038/ni.2681
  108. Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1
  109. Sugiura H, 2012, RESPIROLOGY, V17, P533, DOI 10.1111/j.1440-1843.2012.02136.x
  110. Sun SQ, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00060
  111. Teunissen CE, 2003, NEUROSCI LETT, V347, P159, DOI 10.1016/S0304-3940(03)00667-0
  112. Traversari C, 2014, EUR J IMMUNOL, V44, P1896, DOI 10.1002/eji.201344292
  113. Traversari C, 2012, CURR OPIN PHARMACOL, V12, P729, DOI 10.1016/j.coph.2012.07.003
  114. Trindade BC, 2021, IMMUNITY, V54, P2273, DOI 10.1016/j.immuni.2021.09.004
  115. Trousson A, 2009, J NEUROCHEM, V109, P945, DOI 10.1111/j.1471-4159.2009.06009.x
  116. BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993
  117. Unsworth AJ, 2018, CARDIOVASC RES, V114, P645, DOI 10.1093/cvr/cvy044
  118. Varaksa T, 2021, J MOL BIOL, V433, DOI 10.1016/j.jmb.2020.166763
  119. Vejux A, 2008, BRAZ J MED BIOL RES, V41, P545, DOI 10.1590/S0100-879X2008000700001
  120. Vejux A, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00012
  121. Villablanca EJ, 2010, NAT MED, V16, P98, DOI 10.1038/nm.2074
  122. Wanke F, 2017, CELL REP, V18, P1270, DOI 10.1016/j.celrep.2017.01.020
  123. Wilkins C, 2013, IMMUNITY, V38, P3, DOI 10.1016/j.immuni.2013.01.002
  124. Willinger T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02010
  125. Wyss A, 2019, MUCOSAL IMMUNOL, V12, P733, DOI 10.1038/s41385-019-0140-x
  126. Yang X, 2007, COLD SPRING HARB SYM, V72, P387, DOI 10.1101/sqb.2007.72.058
  127. Bjornevik K, 2022, SCIENCE, V375, P296, DOI 10.1126/science.abj8222
  128. Yi TS, 2012, IMMUNITY, V37, P535, DOI 10.1016/j.immuni.2012.06.015
  129. York AG, 2013, J EXP MED, V210, P1653, DOI 10.1084/jem.20131335
  130. Yoshioka N, 2005, FREE RADICAL RES, V39, P299, DOI 10.1080/10715760400023002
  131. Yu EM, 2015, ANTICANCER RES, V35, P5149
  132. Zakyrjanova GF, 2021, FREE RADICAL BIO MED, V174, P121, DOI 10.1016/j.freeradbiomed.2021.08.013
  133. Zakyrjanova GF, 2021, LIFE SCI, V273, DOI 10.1016/j.lfs.2021.119300
  134. Zanjani BN, 2022, J ASTHMA, DOI 10.1080/02770903.2022.2045310
  135. Zarrouk A, 2014, AGEING RES REV, V18, P148, DOI 10.1016/j.arr.2014.09.006
  136. Zhang PP, 2015, CELL RES, V25, P1093, DOI 10.1038/cr.2015.109
  137. Zhang Y, 2018, J NEUROL SCI, V390, P162, DOI 10.1016/j.jns.2018.04.037
  138. Blanc M, 2013, IMMUNITY, V38, P106, DOI 10.1016/j.immuni.2012.11.004
  139. Zhao J, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070727
  140. Bottemanne P, 2021, FASEB J, V35, DOI 10.1096/fj.202002555R
  141. Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8
  142. Chalmin F, 2015, J AUTOIMMUN, V56, P45, DOI 10.1016/j.jaut.2014.10.001
  143. Chalubinski M, 2013, INFLAMM RES, V62, P1015, DOI 10.1007/s00011-013-0660-x
  144. Crick PJ, 2017, MOL NEUROBIOL, V54, P8009, DOI 10.1007/s12035-016-0281-9
  145. Cui GL, 2011, J CLIN INVEST, V121, P658, DOI 10.1172/JCI42974
  146. Cyster JG, 2014, NAT REV IMMUNOL, V14, P731, DOI 10.1038/nri3755
  147. Dang EV, 2017, CELL, V171, P1057, DOI 10.1016/j.cell.2017.09.029
  148. Daugvilaite V, 2014, EUR J IMMUNOL, V44, P1904, DOI 10.1002/eji.201444493
  149. de Freitas FA, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092301
  150. Dennis EA, 2010, J BIOL CHEM, V285, P39976, DOI 10.1074/jbc.M110.182915
  151. Dias IHK, 2020, ANTIOXID REDOX SIGN, V33, P166, DOI 10.1089/ars.2020.8022
  152. Diczfalusy U, 2009, J LIPID RES, V50, P2258, DOI 10.1194/jlr.M900107-JLR200
  153. Diestel A, 2003, J EXP MED, V198, P1729, DOI 10.1084/jem.20030975
  154. Dodge JC, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80378-y
  155. Duc D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184522
  156. Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022
  157. Emgard J, 2018, IMMUNITY, V48, P120, DOI 10.1016/j.immuni.2017.11.020
  158. Fang F, 2019, ONCOTARGETS THER, V12, P685, DOI 10.2147/OTT.S180534
  159. Favero Giovani M, 2018, Oncotarget, V9, P14160, DOI 10.18632/oncotarget.24389
  160. Ferderbar S, 2007, DIABETES-METAB RES, V23, P35, DOI 10.1002/dmrr.645
  161. Fernandes LR, 2017, J PROTEOMICS, V151, P12, DOI 10.1016/j.jprot.2016.06.011